MAOIs in the contemporary treatment of depression

Michael E. Thase, Madhukar H. Trivedi, A. John Rush

Research output: Contribution to journalArticle

189 Citations (Scopus)

Abstract

We review the literature on the effectiveness of the monoamine oxidase inhibitors (MAOIs) and present metaanalyses of controlled trials comparing the FDA-approved MAOIs with both placebo and comparator tricyclic antidepressants. For outpatients, metaanalyses with intent-to-treat samples revealed generally comparable overall efficacy for phenelzine, isocarboxazid, and tranylcypromine. Drug-placebo differences were 29.5% (± 11.1%) (phenelzine; nine studies), 41.3% (± 18.0%) (isocarboxazid; three studies), and 22.1% (± 25.4%) (tranylcypromine; three studies). For inpatients, phenelzine was 22.3% (± 30.7%) (five studies) more effective than placebo, whereas the isocarboxazid-placebo difference was lower (15.3%) (± 12.6%). Both phenelzine and isocarboxazid were significantly less effective than comparator tricyclics for inpatients, whereas tranylcypromine has not been adequately studied. Both phenelzine and tranylcypromine appear to be more effective than tricyclics in depressed outpatients with atypical features. Monoamine oxidase inhibitors are also effective treatments for outpatients who have failed to respond to tricyclic antidepressants. Our review also suggests (1) the FDA-approved MAOIs treat a somewhat different group of patients than tricyclics; (2) more severely depressed inpatients may not respond as well to MAOIs as to tricyclics; and (3) because of preferential MAOI responsivity, atypical or anergic depressions may be biologically different than classical depressions.

Original languageEnglish (US)
Pages (from-to)185-219
Number of pages35
JournalNeuropsychopharmacology
Volume12
Issue number3
DOIs
StatePublished - 1995

Fingerprint

Phenelzine
Monoamine Oxidase Inhibitors
Isocarboxazid
Tranylcypromine
Placebos
Inpatients
Outpatients
Tricyclic Antidepressive Agents
Therapeutics
Pharmaceutical Preparations

Keywords

  • Antidepressant efficacy
  • Depression
  • Isocarboxazid
  • MAOIs
  • Metaanalysis
  • Phenelzine
  • Tranylcypromine

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Pharmacology

Cite this

MAOIs in the contemporary treatment of depression. / Thase, Michael E.; Trivedi, Madhukar H.; Rush, A. John.

In: Neuropsychopharmacology, Vol. 12, No. 3, 1995, p. 185-219.

Research output: Contribution to journalArticle

Thase, Michael E. ; Trivedi, Madhukar H. ; Rush, A. John. / MAOIs in the contemporary treatment of depression. In: Neuropsychopharmacology. 1995 ; Vol. 12, No. 3. pp. 185-219.
@article{45ac0aa077ff4238947c70d1972a2fa5,
title = "MAOIs in the contemporary treatment of depression",
abstract = "We review the literature on the effectiveness of the monoamine oxidase inhibitors (MAOIs) and present metaanalyses of controlled trials comparing the FDA-approved MAOIs with both placebo and comparator tricyclic antidepressants. For outpatients, metaanalyses with intent-to-treat samples revealed generally comparable overall efficacy for phenelzine, isocarboxazid, and tranylcypromine. Drug-placebo differences were 29.5{\%} (± 11.1{\%}) (phenelzine; nine studies), 41.3{\%} (± 18.0{\%}) (isocarboxazid; three studies), and 22.1{\%} (± 25.4{\%}) (tranylcypromine; three studies). For inpatients, phenelzine was 22.3{\%} (± 30.7{\%}) (five studies) more effective than placebo, whereas the isocarboxazid-placebo difference was lower (15.3{\%}) (± 12.6{\%}). Both phenelzine and isocarboxazid were significantly less effective than comparator tricyclics for inpatients, whereas tranylcypromine has not been adequately studied. Both phenelzine and tranylcypromine appear to be more effective than tricyclics in depressed outpatients with atypical features. Monoamine oxidase inhibitors are also effective treatments for outpatients who have failed to respond to tricyclic antidepressants. Our review also suggests (1) the FDA-approved MAOIs treat a somewhat different group of patients than tricyclics; (2) more severely depressed inpatients may not respond as well to MAOIs as to tricyclics; and (3) because of preferential MAOI responsivity, atypical or anergic depressions may be biologically different than classical depressions.",
keywords = "Antidepressant efficacy, Depression, Isocarboxazid, MAOIs, Metaanalysis, Phenelzine, Tranylcypromine",
author = "Thase, {Michael E.} and Trivedi, {Madhukar H.} and Rush, {A. John}",
year = "1995",
doi = "10.1016/0893-133X(94)00058-8",
language = "English (US)",
volume = "12",
pages = "185--219",
journal = "Neuropsychopharmacology",
issn = "0893-133X",
publisher = "Nature Publishing Group",
number = "3",

}

TY - JOUR

T1 - MAOIs in the contemporary treatment of depression

AU - Thase, Michael E.

AU - Trivedi, Madhukar H.

AU - Rush, A. John

PY - 1995

Y1 - 1995

N2 - We review the literature on the effectiveness of the monoamine oxidase inhibitors (MAOIs) and present metaanalyses of controlled trials comparing the FDA-approved MAOIs with both placebo and comparator tricyclic antidepressants. For outpatients, metaanalyses with intent-to-treat samples revealed generally comparable overall efficacy for phenelzine, isocarboxazid, and tranylcypromine. Drug-placebo differences were 29.5% (± 11.1%) (phenelzine; nine studies), 41.3% (± 18.0%) (isocarboxazid; three studies), and 22.1% (± 25.4%) (tranylcypromine; three studies). For inpatients, phenelzine was 22.3% (± 30.7%) (five studies) more effective than placebo, whereas the isocarboxazid-placebo difference was lower (15.3%) (± 12.6%). Both phenelzine and isocarboxazid were significantly less effective than comparator tricyclics for inpatients, whereas tranylcypromine has not been adequately studied. Both phenelzine and tranylcypromine appear to be more effective than tricyclics in depressed outpatients with atypical features. Monoamine oxidase inhibitors are also effective treatments for outpatients who have failed to respond to tricyclic antidepressants. Our review also suggests (1) the FDA-approved MAOIs treat a somewhat different group of patients than tricyclics; (2) more severely depressed inpatients may not respond as well to MAOIs as to tricyclics; and (3) because of preferential MAOI responsivity, atypical or anergic depressions may be biologically different than classical depressions.

AB - We review the literature on the effectiveness of the monoamine oxidase inhibitors (MAOIs) and present metaanalyses of controlled trials comparing the FDA-approved MAOIs with both placebo and comparator tricyclic antidepressants. For outpatients, metaanalyses with intent-to-treat samples revealed generally comparable overall efficacy for phenelzine, isocarboxazid, and tranylcypromine. Drug-placebo differences were 29.5% (± 11.1%) (phenelzine; nine studies), 41.3% (± 18.0%) (isocarboxazid; three studies), and 22.1% (± 25.4%) (tranylcypromine; three studies). For inpatients, phenelzine was 22.3% (± 30.7%) (five studies) more effective than placebo, whereas the isocarboxazid-placebo difference was lower (15.3%) (± 12.6%). Both phenelzine and isocarboxazid were significantly less effective than comparator tricyclics for inpatients, whereas tranylcypromine has not been adequately studied. Both phenelzine and tranylcypromine appear to be more effective than tricyclics in depressed outpatients with atypical features. Monoamine oxidase inhibitors are also effective treatments for outpatients who have failed to respond to tricyclic antidepressants. Our review also suggests (1) the FDA-approved MAOIs treat a somewhat different group of patients than tricyclics; (2) more severely depressed inpatients may not respond as well to MAOIs as to tricyclics; and (3) because of preferential MAOI responsivity, atypical or anergic depressions may be biologically different than classical depressions.

KW - Antidepressant efficacy

KW - Depression

KW - Isocarboxazid

KW - MAOIs

KW - Metaanalysis

KW - Phenelzine

KW - Tranylcypromine

UR - http://www.scopus.com/inward/record.url?scp=0029010468&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029010468&partnerID=8YFLogxK

U2 - 10.1016/0893-133X(94)00058-8

DO - 10.1016/0893-133X(94)00058-8

M3 - Article

C2 - 7612154

AN - SCOPUS:0029010468

VL - 12

SP - 185

EP - 219

JO - Neuropsychopharmacology

JF - Neuropsychopharmacology

SN - 0893-133X

IS - 3

ER -